Bris­tol My­ers li­cens­es for Evotec mol­e­cule for $20M; FDA ap­proves Im­pel's mi­graine nasal spray Trud­he­sa

Bris­tol My­ers Squibb has ex­er­cised its op­tion with Evotec for EVT8683, a small mol­e­cule cre­at­ed by the Ger­man biotech to tar­get a spe­cif­ic “cel­lu­lar stress re­sponse.”

The com­pa­nies have ob­tained clear­ance to start hu­man tri­als, close to 4.5 years af­ter ini­ti­at­ing a part­ner­ship.

Ac­cord­ing to an Evotec state­ment, “the pro­gramme tar­gets a key cel­lu­lar stress re­sponse mech­a­nism which has the po­ten­tial to de­liv­er dis­ease-mod­i­fy­ing treat­ments for sev­er­al dev­as­tat­ing neu­rode­gen­er­a­tive dis­eases.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN